AntibodySystem는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
Anti-Atezolizumab ELISA Kit
제품 번호
KAJ70101
제품 특징
KAJ70101
PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Atezolizumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Atezolizumab will be captured by immobilized Atezolizumab. After washing away any unbound substances, a biotin-labeled Atezolizumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Atezolizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Used for the quantitative determination of Anti-Atezolizumab concentration in serum and plasma.
Colorimetric
Plasma, Serum
Quantitative
1.56 - 100 ng/mL
0.78 ng/mL
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
| Intra-Assay Precision | Inter-Assay Precision | ||||
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 16 | 16 | 16 | 24 | 24 | 24 |
Mean (ng/mL) | 47.6 | 11.8 | 2.5 | 49.0 | 11.7 | 3.1 |
Standard deviation | 1.3 | 0.5 | 0.1 | 1.8 | 0.4 | 0.2 |
CV (%) | 2.8 | 4.4 | 5.6 | 3.7 | 3.6 | 7.0 |
80-120%
2-8 ℃
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
MPDL3280A,RG7446,CAS: 1380723-44-3
Data Image
References
Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances., PMID:40515614
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study., PMID:40507295
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations., PMID:40507271
Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database., PMID:40506075
Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data., PMID:40494842
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population., PMID:40494131
Implementing performance-based risk-sharing agreements in non-small cell lung cancer immunotherapy: a real-world data case study., PMID:40489036
LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma., PMID:40483310
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma., PMID:40479621
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis., PMID:40474015
The current and emerging immunotherapy paradigm in small-cell lung cancer., PMID:40473974
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., PMID:40473449
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)., PMID:40473339
Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review., PMID:40471689
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report., PMID:40470485
Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial., PMID:40468525
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial., PMID:40467898
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial., PMID:40467896
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria., PMID:40448543
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial., PMID:40446184
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers., PMID:40442146
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., PMID:40439364
Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons., PMID:40438876
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma., PMID:40438087
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab., PMID:40434907
Intrahepatic Lymphoid Follicles Comprising T and B Cells Mimic Hepatocellular Carcinoma in a Hepatitis B Patient., PMID:40429964
Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus., PMID:40426858
Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps., PMID:40421971
Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis., PMID:40418927
Immunotherapy in Triple-Negative Breast Cancer., PMID:40418298
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade., PMID:40416959
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma., PMID:40416920
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab., PMID:40407727
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer., PMID:40404526
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel., PMID:40404206
Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study., PMID:40395491
Photoimmuno-Lure Nanoplatform for Enhancing T Cell Expansion in Glioblastoma via Synergistic Treatment of Photodynamic Therapy and Immune Checkpoint Inhibition., PMID:40395101
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)., PMID:40391393
Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma., PMID:40387956
Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans., PMID:40387909
Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma., PMID:40387836
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer., PMID:40386714
Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy., PMID:40385627
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma., PMID:40384918
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial., PMID:40379995
Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study., PMID:40379142
AntibodySystem의 모든 제품들을 만나 보세요!
Antibodysystem - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"
MSDS
온라인 견적
